Biocon Limited
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
What Biocon files
- Updates91
- Others75
- Important67
- Investor Meet62
- Board Meeting23
- PPTs9
Biocon has paid its final dividend for the recent financial year. Shareholders received ₹0.50 per equity share directly in their accounts, following approval at the AGM.
Biocon's consolidated income rose 9% to Rs 4,391 Cr, with net profit surging 355% to Rs 141 Cr. Biopharma revenue jumped 17% on new US/EU biosimilar/generic launches and EMA approval for its Malaysia plant, offsetting challenges in Services.
Biocon launched Yesafili™, an interchangeable biosimilar to Eylea® 2 mg, in the U.S. This US FDA-approved product targets ~20 million adults with serious eye conditions, entering a market with over $5.89 billion in annual sales.
Biocon launched Yesafili™ (biosimilar Aflibercept) in the U.S., an FDA-approved interchangeable biosimilar to Eylea® 2 mg. This expands Biocon's ophthalmology presence in a ~$5.89 billion market, offering a key treatment for eye conditions like age-related macular degeneration.
Biocon announced pivotal clinical data publications reinforcing its Yesafili™ (Eylea® biosimilar) effectiveness and equivalence. This milestone strengthens its upcoming U.S. launch, expanding patient access and positioning the company for significant market penetration.